Apriori Bio and A*STAR Infectious Diseases Labs Announce strategic partnership to advance next generation influenza vaccines

By Linda Stewart2025-11-18T12:02:00+00:00

No comments

Apriori Bio, a Flagship Pioneering company focused on developing prospective, variant-resilient vaccines, and the Agency for Science, Technology and Research Infectious Diseases Labs (A*STAR IDL) announced a strategic research partnership to co-develop and evaluate next generation self-amplifying RNA (saRNA) vaccines targeting seasonal and pandemic influenza. The collaboration brings together Apriori’s Octavia™ platform for intelligent, prospective antigen design with A*STAR IDL’s saRNA delivery technology, and will initially focus on improved H5 influenza vaccines that anticipate infection in humans.

H1N1_Influenza_Virus_Particles_(8411599236)

Source: NIAID

Colorized transmission electron micrograph showing H1N1 influenza virus particles.

“This collaboration is an important step for Apriori as we unite complementary strengths in vaccine design and delivery to drive lasting immunity against one of the world’s most challenging viruses,” said Craig Williams, MBA, Chief Executive Officer of Apriori Bio and CEO-Partner at Flagship Pioneering. “Apriori has redefined what’s possible in vaccine development by harnessing the power of AI to predict viral evolution and protect people against pathogens that outpace traditional approaches, such as influenza. Together, with A*STAR IDL’s next generation RNA delivery capabilities, we aim to change the standard of protection for patients worldwide.”

Professor Lisa Ng, Executive Director of A*STAR IDL, said, “This collaboration reflects our shared commitment to translating research into real-world impact. By combining A*STAR IDL’s strengths in RNA and infectious disease expertise with Apriori’s AI-guided antigen design, we aim to accelerate vaccine development and strengthen preparedness for future outbreaks in Singapore and globally.”

Compelling solutions

Harry Kleanthous, Ph.D., Chief Scientific Officer of Apriori Bio, added, “Today’s vaccines against H5 influenza have shown limitations in achieving both robust single-dose immunity and breadth of protection against emerging viral variants. saRNA offers a compelling solution to deliver durable protection from a single dose, while Apriori’s Octavia™-generated antigen sequence would provide enhanced coverage. By addressing both of these critical unmet needs, we aim to develop the first anticipatory H5 vaccine to build a healthier future.”

Ms Irene Cheong, Assistant Chief Executive of A*STAR Innovation and Enterprise, added, “This partnership between A*STAR and Apriori Bio brings together complementary expertise in RNA and vaccine science that can better protect populations and strengthen global health security. A*STAR is excited to partner with another Flagship portfolio company with cutting-edge technologies to advance novel solutions for human health.”

The collaboration takes place under Flagship Pioneering’s ongoing institutional partnership with A*STAR, which aims to jointly advance breakthrough solutions for the advancement of human health, as well as to advance Singapore’s position as a global hub for biotechnological innovations.

Topics

No comments

News
Vaccine skepticism on social media can predict public health crises

2025-11-18T13:02:00Z By Linda Stewart

Researchers have developed a new approach that could help public health officials predict where outbreaks might occur. By analyzing social media posts, the method identifies early signs of increasing vaccine skepticism — a warning signal that could emerge before any disease begins to spread.
News
Micropores pave the way for infection research

2025-11-18T12:50:00Z By Linda Stewart

Organ-on-a-chip technology often contains gels that imitate the 3D environment of our tissues - however, many of these gels are too dense, hindering the passage of microbes and immune cells, and movement is essential to recreate how infections really develop. In this study, the research team developed a new type of porous gel that solves this problem.
News
Time to act and not react: how can the European Union turn the tide of antimicrobial resistance?

2025-11-18T12:28:00Z By Linda Stewart

Despite determined efforts by countries and healthcare professionals, Europe is not on track to meet four of the five AMR targets set by the EU Council for 2030*, according to data released on EAAD.

No comments yet

You're not signed in.

Only registered users can comment on this article.

More from News

News
Medications change our gut microbiome in predictable ways

2025-11-18T11:32:00Z By Linda Stewart

A study shows that many of the changes to the gut microbiome are driven by competition for nutrients – medications reduce certain bacterial populations and change the availability of nutrients, and the bacteria most able to capitalize on those changes are the ones to survive.
News
Wastewater from most countries favours non-resistant bacteria

2025-11-18T11:14:00Z By Linda Stewart

Municipal wastewater contains a large range of excreted antibiotics and has therefore long been suspected to be a spawning ground for antibiotic-resistant bacteria. By testing the potential of untreated municipal wastewater from 47 countries to select for resistant E. coli, researchers show that while some samples indeed do so, most instead suppress them.
News
Hepatitis E virus from rats can also infect humans in individual cases – a new zoonotic pathogen?

2025-11-18T11:01:00Z By Linda Stewart

It has only been known for a few years that humans can also be infected with a variant of the hepatitis E virus that is usually prevalent in rats. Following reports of individual cases, mainly from Hong Kong and Spain, the first infection with ratHEV has now also been described in a patient from Germany.